Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Stem cell-engineered inkt cell-based off-the-shelf cellular therapy

An engineering and cellular technology, applied in genetic engineering, non-embryonic pluripotent stem cells, receptors/cell surface antigens/cell surface determinants, etc., can solve cancer patient toxicity and other issues

Pending Publication Date: 2021-03-16
RGT UNIV OF CALIFORNIA
View PDF31 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Despite existing therapies, cancer patients still suffer from the risk of ineffectiveness, toxicity and recurrence of these treatments

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Stem cell-engineered inkt cell-based off-the-shelf cellular therapy
  • Stem cell-engineered inkt cell-based off-the-shelf cellular therapy
  • Stem cell-engineered inkt cell-based off-the-shelf cellular therapy

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0208] The preparation methods of the present disclosure can produce compounds comprising at least about 10 2 to 10 6 A cloned iNKT cell population of cloned iNKT cells. The method can produce at least about 10 6 to 10 12 cell population of total cells. The resulting cell population can be frozen and then thawed. In certain instances of the method of preparation, the method further comprises introducing into the frozen and thawed population of cells one or more other nucleic acids, eg, such as one or more other nucleic acids encoding one or more therapeutic gene products.

[0209] In certain embodiments, methods of developing 3D culture compositions (eg, ATO production) involving use of human DLL1 (MS5-hDLL1, below) and mobilized peripheral cells isolated from human umbilical cord blood, bone marrow, or G-CSF can be provided blood CD34 + HSPC-transduced aggregates of the MS-5 murine stromal cell line. up to 1x10 6 Individual HSPCs were mixed with MS5-hDLL1 cells in an ...

Embodiment 1

[0324] Example 1: Hematopoietic stem cell (HSC) method for engineering off-the-shelf INKT cells

[0325] This example relates to the generation of ready-made iNKT cells comprising deficient or down-regulated surface expression of one or more HLA-I and / or HLA-II molecules. In specific embodiments, iNKT cells are expanded from healthy donor peripheral blood mononuclear cells (PBMCs) and then CRISPR-Cas9 engineered to knock out B2M and CIITA genes. Due to the high variability and low frequency of iNKT cells in the human population (approximately 0.001-0.1% in blood), it would be beneficial to create methods that allow alternative means of obtaining iNKT cells.

[0326] The present disclosure provides a powerful method to generate iNKT cells from hematopoietic stem cells (HSCs) by genetically engineering HSCs with iNKT TCRs and programming these HSCs to develop into iNKT cells (Smith et al., 2015). This approach exploits two molecular mechanisms that control iNKT cell development...

Embodiment approach

[0363] Overview of CMC In certain embodiments, manufacturing U HSC-iNKT involves: 1) collection of G-CSF-mobilized leukopak; 2) purification of G-CSF-leukopak to CD34 + 3) Transduction of HSCs with lentiviral vector Lenti / iNKT-sr39TK; 4) Gene editing of B2M and CIITA by CRISPR / Cas9; 5) in vitro differentiation into iNKT cells by ATO; 6) purification of iNKT cells; 7) In vitro cell expansion; 8) Cell collection, preparation and cryopreservation ( Figure 14 ). As an example, there are two drug substances (Lenti / iNKT-sr39TK vector and U HSC-iNKT cells), and at least in some cases the final drug product is formulated and cryopreserved in an infusion bag U HSC-iNKTs.

[0364] 1. Vector manufacturing

[0365] Vector structure One vector used to genetically engineer HSCs into iNKT cells is the HIV-1-derived lentiviral vector Lenti / iNKT-sr39TK, which encodes the human iNKT TCR gene and the sr39TK PET imaging / suicide gene ( Figure 13 ). The key components of this third-generat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Embodiments of the disclosure include compositions and methods related to engineered invariant natural killer T (iNKT) cells for off-the-shelf use for clinical therapy. In particular embodiments, theiNKT cells are produced from hematopoietic stem progenitorcells and also are suitable for allogeneic cellular therapy because they are HLA negative. In specific embodiments, the cells are cultured ina particular in vitro three-dimensional artificial thymic organoid system and the cells have imaging and suicide targeting capabilities.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS [0002] This application claims the benefit of US Provisional Application No. 62 / 683,750, filed June 12, 2018, the contents of which are incorporated herein by reference in their entirety. [0003] Field of Invention [0004] Embodiments of the present disclosure relate at least to the fields of immunology, cell biology, molecular biology, and medicine, including at least cancer drugs. [0005] Background of the Invention [0006] Cancer affects tens of millions of people worldwide and is a major threat to public health in the United States and California. Cancer is the second leading cause of death in California, killing more than 56,000 people each year and having a devastating impact on the state's economy. Despite existing therapies, cancer patients still suffer from the inefficiency of these treatments, their toxicity and the risk of recurrence. Therefore, new treatments for cancer are urgently needed. In the past decade,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/14A61K35/17C12N5/074C12N5/0783C12N9/22C12N15/09C12N15/11C12N15/12C12N15/33C12N15/52C12N15/63A61P35/00
CPCC12N15/1138C12N15/113C12N2310/20C07K14/7051C07K14/70539A61K38/00A61K39/4621A61K39/4644A61K39/46434C12N5/0646A61K2239/57A61K2239/38A61K2239/26A61K2239/31A61K2239/48A61K39/4613C12N15/86C12N2502/1185C12N2740/15043
Inventor L.杨Y.朱C.西特A.蒙特尔-哈根G.M.克鲁克斯
Owner RGT UNIV OF CALIFORNIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com